August 2018

Contents

Editorial

• 24 August 2018: vol 19 no 14: AIDS 2018 – next reports…

• 03 August 2018: vol 19 no 13: AIDS 2018 – first reports

Conference reports

• 22nd International AIDS Conference (AIDS 2018) – second reports

• Namibia close to achieving 90-90-90 targets

• Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

• Changing comorbidities in HIV positive people older than 60 at London clinic

• High acceptability of annual digital (finger) exam for early detection of anal cancer in gay men >35 years old

• High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination

• HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands

• FDA-approved compounds that might selectively reverse HIV latency

• Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans

• Janssen HIV vaccine: update from APPROACH and largescale efficacy study

• Viral load testing in Latin America and the Caribbean

• Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire

• Resolving a diagnosis for people with persistently indeterminate HIV test results

• 10th International Workshop on HIV Paediatrics – second reports

• Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy

• 22nd International AIDS Conference (AIDS 2018) – first reports

• Caution on press conference news from AIDS 2018

• Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV

• DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study

• Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study  

• Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil 

• WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)

• No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

• Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1

• First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough

• Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

• Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians

• AIDS 2018 online: links to selected webcasts

• 10th International Workshop on HIV Paediatrics – first reports

• Preconception safety signal with dolutegravir: data from the Tsepamo study

Antiretrovirals

• Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections

• Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates

Other news

• More than ten people a day died from drug-related deaths in England and Wales last year:

On the web

• We learn, we think, we change: Martin Fisher Foundation and Stiggy launch campaign to end stigma

PDFs

• 24 August 2018: vol 19 no 14

• 03 August 2018: vol 19 no 13